Vazquez-Urrutia Jorge Raul, Torres-Bustamante Maria Iyali, Cerda-Cruz Cesar Rodrigo, Bravo-Cuellar Alejandro, Ortiz-Lazareno Pablo Cesar
Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México & Dirección General de Calidad y Educación en Salud, Secretaría de Salud, México.
Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos, México.
Future Oncol. 2023 Jan;19(1):77-93. doi: 10.2217/fon-2022-0891. Epub 2023 Jan 27.
To date, prostate cancer remains the most common tumor diagnosed in males and the second most common cause of cancer-related mortality. While current screening protocols can detect early disease, they lack enough sensitivity and specificity, leading to unnecessary biopsies and overtreatment. Furthermore, disease monitoring remains challenging, as current prognostic strategies rely on data obtained by invasive means such as biopsy, surgery and digital rectal examination. Additionally, there are no tools to predict tumor progression, risk reclassification and treatment response. As the need for accurate biomarkers continues, miRNAs are promising biomarkers for screening, surveillance, prognosis and treatment response in prostate cancer. In this review, the authors describe the current evidence regarding the accuracy and efficacy of these biomarkers for prostate cancer.
迄今为止，前列腺癌仍是男性中诊断出的最常见肿瘤，也是癌症相关死亡的第二大常见原因。虽然目前的筛查方案能够检测出早期疾病，但它们缺乏足够的敏感性和特异性，导致不必要的活检和过度治疗。此外，疾病监测仍然具有挑战性，因为目前的预后策略依赖于通过活检、手术和直肠指检等侵入性手段获得的数据。此外，目前还没有预测肿瘤进展、风险重新分类和治疗反应的工具。随着对准确生物标志物需求的持续存在，微小RNA是前列腺癌筛查、监测、预后和治疗反应方面很有前景的生物标志物。在这篇综述中，作者描述了目前关于这些生物标志物用于前列腺癌的准确性和有效性的证据。
